Investigational New Drugs

, Volume 15, Issue 1, pp 49–59 | Cite as

An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action

  • William J. Gradishar


Angiogenesis is a biologic process whereby endothelial cells divide and migrate to form new blood vessels. This process is required in physiological conditions, but is also a necessary requirement for solid tumors to grow and metastasize. Over the last several years, the growth factors that have both a positive and negative influence on tumor angiogenesis have been delineated. Interfering with tumor angiogenesis was considered a potential therapeutic strategy 25 years ago, but only recently have compounds with an ability to interfere with angiogenesis entered clinical trials. This review will discuss the first generation of angiogenesis inhibitors, their mechanism of action and data from clinical trials.

angiogenesis therapy inhibitors 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1:27–31, 1995Google Scholar
  2. 2.
    Bouck N, Stellmach V, Hsu F: How tumors become angiogenic. Adv Cancer Res, in press, 1995Google Scholar
  3. 3.
    Folkman J: Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds) The Molecular Basis of Cancer. WB Saunders, Philadelphia, 1995, pp 206–232Google Scholar
  4. 4.
    O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328, 1994Google Scholar
  5. 5.
    Brooks PC, Strömblad S, Klemke R, Visscher D, Sarker FH, Cheresh DA: Anti-integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815–1822, 1995Google Scholar
  6. 6.
    Damsky CH: Starve a tumor: Therapeutic advice for breast cancer? J Clin Invest 96:1696–1697, 1995Google Scholar
  7. 7.
    Platanias LC: Interferons: laboratory to clinic investigations. Current Opinion in Oncology 7:560–565, 1995Google Scholar
  8. 8.
    Itri LM: The interferons. Cancer 70:940–945, 1992Google Scholar
  9. 9.
    Brouty-Boye D, Zetter B: Inhibition of cell motility by interferon. Science 108:516–518, 1980Google Scholar
  10. 10.
    Friesel R, Komariya A, Maciag T: Inhibition of endothelial cell proliferation by gamma interferon. J Cell Biol 104:689–696, 1987Google Scholar
  11. 11.
    Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler I: Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92:4562–4566, 1995Google Scholar
  12. 12.
    Brem H, Gresser I, Grosfeld J, Folkman J: The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 28:1253–1257, 1993Google Scholar
  13. 13.
    White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL: Treatment of pulmonary hemangiomatosis with recombinant interferon alpha-2a. N Engl J Med 320:1197–1200, 1989Google Scholar
  14. 14.
    Ezekowitz RAB, Mulliken JB, Folkman J: Interferon alpha-2a therapy for life threatening hemangiomas of infancy. N Engl J Med 326: 1456–1463, 1992Google Scholar
  15. 15.
    Lippman SM, Kavanaugh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes Casillas P, Hong WK, Holdener E, Krakoff IH: 13-Cis-retinoic acid plus interferon-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241–245, 1992Google Scholar
  16. 16.
    Lippman SM, Parkinson DR, Itri LM, Weber LS, Schartz SP, Ota DM, Shusterman MA, Krakoff IH, Gutterman JV, Hong WK: 13-Cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235–241, 1992Google Scholar
  17. 17.
    Athanasiadis I, Kies MS, Miller M, Ganzenko N, Joob A, Marymont M, Rademaker A, Gradishar WJ: Phase II study of all-trans-retinoic acid and α-interferon in patients with advanced non-small cell lung cancer. Clin Cancer Res 1:973–979, 1995Google Scholar
  18. 18.
    Nakamura S, Sakurada S, Salahuddin S, Osada Y, Tanaka N, Sakamato N, Sekguchi M, Gallo R: Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science 255:1437–1440, 1992Google Scholar
  19. 19.
    Nakayama Y, Iwahana M, Sakamoto N, Tanaka NG, Osada Y: Inhibitory effects of a bacteria-derived sulfated polysaccharide against basic fibroblast growth factor-induced endothelial cell growth and chemotaxis. J Cell Physiol 154:1–6, 1993Google Scholar
  20. 20.
    Eckhardt SG, Burris HA, Eckhard JR, Weiss G, Rinaldi D, Barrington R, Smith L, Fields S, Kuhn J, Smith S, Smetzer L, Marcus S, Masuo K, Sobel R, Von Hoff DD: Phase I assessment of the novel angiogenesis inhibitor DS4152 (tecogalan sodium). Proc Am Soc Clin Oncol 13:55 (abstract 23), 1994Google Scholar
  21. 21.
    Tulpule A, Snyder JC, Espina BM, Higashi L, Satomi M, Lombardy EE, Gill PS: A phase I study of tecogalan, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi's sarcoma and solid tumors. Blood 84:248a(abstract 976), 1994Google Scholar
  22. 22.
    Wellstein A, Zugmaier G, Califano J, Kern F, Paik S, Lippman ME: Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 83:716–720, 1993Google Scholar
  23. 23.
    Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, Kern FG: Autocrine growth stimulation by secreted K-FGF but not endogenous basic FGF. Cell Growth Diff 1:63–71, 1990Google Scholar
  24. 24.
    Parker BW, Swain SM, Zugmaier G, DeLap RL, Lippman ME, Wellstein A: Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. J Natl Cancer Inst 85:1068–1073, 1993Google Scholar
  25. 25.
    Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 84:1716–1724, 1992Google Scholar
  26. 26.
    Pluda JM, Shay LE, Foli A, Tannenbaum S, Cohen PJ, Goldspiel BR, Adamo D, Cooper MR, Broher S, Yarchoan R: Administration of pentosan polysulfate to patients with human immunodeficiency virus associated Kaposi's sarcoma. J Natl Cancer Inst 85:1585–1592, 1993Google Scholar
  27. 27.
    Schwartsmann G, Mans DRA, Machado VL, Sander E, Sprinz E, Kalakum L: Phase II study of the basic fibroblast growth factor-inhibiting agent pentosan polysulfate in patients with AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 14:290(abstract 827), 1995Google Scholar
  28. 28.
    Voogd TE, Vansterkenburg ELM, Wilting J, Janssen LHM: Recent research on the biological activity of suramin. Pharmacol Rev 45:177–203, 1993Google Scholar
  29. 29.
    Stein CA: Suramin: A novel antieoplastic agent with multiple potential mechanisms of action. Cancer Res 53:2239–2248, 1993Google Scholar
  30. 30.
    Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54:2654–2660, 1994Google Scholar
  31. 31.
    Gagliardi A, Hadd H, Collins DC: Inhibition of angiogenesis by suramin. Cancer Res 52:5073–5075, 1992Google Scholar
  32. 32.
    Myers C, Cooper M, Stein C, LaRocco R, Walther MM, Weiss G, Choyke P, Dawson N, Steiberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan WM: Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881–889, 1992Google Scholar
  33. 33.
    Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myer CE, Cooper MR: Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 13:2223–2229, 1995Google Scholar
  34. 34.
    Kelly WK, Scher HI, Mazumder M, Pfister D, Curley T, Leibertz C, Cohen L, Vlamis V, Dnistrian A, Schwartz M: Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. J Clin Oncol 13:2214–2222, 1995Google Scholar
  35. 35.
    Kobayashi K, Vokes EE, Vogelzang NJ, Jarisch L, Soliven B, Ratain MJ: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196–2207, 1995Google Scholar
  36. 36.
    Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Zuhowski EG, Sridhara R: Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187–2195, 1995Google Scholar
  37. 37.
    Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jadrell DI, Zuhowski EG, Tkaczuk KH, Lowilt MH, Hemady RK, Jacobs SC, VanEcho D, Egorin MJ: Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13:2174–2186, 1995Google Scholar
  38. 38.
    Clark JW, Chabner BA: Suramin and prostate cancer: where do we go from here? J Clin Oncol 13:2155–2157, 1995Google Scholar
  39. 39.
    Firsching A, Nickel P, Mora P, Alblio B: Antiproliferative and angiostatic activity of suramin analogues. Cancer Res 55:4957–4961, 1995Google Scholar
  40. 40.
    Kaplan KL, Broekman MJ, Chernoff A, Lesznik GR, Drillings M: Platelet alphagranule proteins: studies on release and subcellular localization. Blood 53:604–618, 1979Google Scholar
  41. 41.
    Taylor S, Folkman J: Protamine is an inhibitor of angiogenesis. Nature 297:307–312, 1982Google Scholar
  42. 42.
    Goldberg ID, Stemerman MB, Handin RI: Vascular permeation of platelet factor 4 after endothelial injury. Science 209:611–612, 1980Google Scholar
  43. 43.
    Horton JE, Harper J, Harper E: Platelet factor 4 regulates osteoclastic resorption in vitro. Biochim Biophys Acta 630:459–462, 1980Google Scholar
  44. 44.
    Deuel TF, Senior RM, Chang DC, Griffin GL, Heirikson RL, Kaiser ET: Platelet factor-4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci USA 78:4584–4587, 1980Google Scholar
  45. 45.
    Maione TE, Sharpe RJ: Development of angiogenesis inhibitors for clinical applications. Trends Pharmacol Sci 11:457–461, 1990Google Scholar
  46. 46.
    Poncz MK, Surrey S, LaRocco P, Weiss MJ, Rappaport EF, Conway TM, Schwartz E: Cloning and characterization of platelet factor 4cDNA derived from a human erythroleukemic cell line. Blood 69:219–223, 1987Google Scholar
  47. 47.
    Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77–79, 1990Google Scholar
  48. 48.
    Maione TE, Gray GS, Hunt AJ, Sharpe RJ: Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 51:2077–2083, 1991Google Scholar
  49. 49.
    Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82:848–853, 1990Google Scholar
  50. 50.
    Belman N, Lipton A, Harvey H, Kambic K, Bonnem E, Visconti M: rhuPF4 — phase I study of an angiogenesis inhibitor in metastatic colon cancer. Proc Am Soc Clin Oncol 13:221(abstract 670), 1994Google Scholar
  51. 51.
    Staddon A, Henry D, Bonnem E: A randomized dose finding study of recombinant platelet factor 4 in cutaneous AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 13:50(abstract 3), 1994Google Scholar
  52. 52.
    Hersh EM, Wiggins CE, Crook LL, Bonnem EM: Phase I study of recombinant platelet factor 4 in patients with metastatic melanoma and renal cell carcinoma. Proc Am Soc Clin Oncol 14:488(abstract 1595), 1995Google Scholar
  53. 53.
    Northfelt DW, Robles R, Lang W, Wagner B, Kahn J, Bonnem E: Phase I/II study of intravenous recombinant platelet factor 4 in AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 14:288(abstract 820), 1995Google Scholar
  54. 54.
    Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555–557, 1990Google Scholar
  55. 55.
    Killough JH, Magill GB, Smith RC: The treatment of amebiasis with fumagillin. Science 115:71–72, 1952Google Scholar
  56. 56.
    DiPaolo JA, Tarbell DS, Moore GE: Studies on the carcinolytic activity of fumagillin and some of its derivatives. Antibiot Annu 541-546, 1958–1959Google Scholar
  57. 57.
    Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J: Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69:212–216, 1994Google Scholar
  58. 58.
    Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL: AGM-1470 inhibits growth of glioblastoma cells in vitro and in vivo. Neurosurgery 34:869–875, 1994Google Scholar
  59. 59.
    Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 53:5233–5236, 1993Google Scholar
  60. 60.
    Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53:2566–2570, 1993Google Scholar
  61. 61.
    Kato T, Sato K, Kakinuma H, Matsuda Y: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 54:5143–5147, 1994Google Scholar
  62. 62.
    Toi M, Yamamoto Y, Imazaw T, Takayanagi T, Akutsu K, Tominaga T: Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int J Oncol 3:525–528, 1993Google Scholar
  63. 63.
    Takamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL: Inhibition of angiogenesis and growth of human nervesheath tumors by AGM-470. J Neurosurg 78:470–476, 1993Google Scholar
  64. 64.
    Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57:920–925, 1994Google Scholar
  65. 65.
    Saville MW, Foli A, Broder S, Yarchoan R: In vitro activity of TNP-470, a novel angiogenesis inhibitor, in Kaposi's sarcoma-related spindle cell lines. J Cell Biochem 17E(suppl):22(abstract 147), 1993Google Scholar
  66. 66.
    Pluda JM, Wyvill K, Figg WD, Whitcup SM, Lietzau J, Saville MW, Cohen R, Feigal E, Parks D, Foli A, Bailey J, Broder S, Yarchoan R: A phase I study of angiogenesis inhibitor, TNP-470 (AGM-1470), administered to patients with HIV-associated Kaposi's sarcoma. Proc Am Soc Clin Oncol 13:51(abstract 8), 1994Google Scholar
  67. 67.
    Zukiwski A, Gutterman J, Bui C, Sella A, Ellerhorst J, Tu S, Amato R, Figg W, Kilbourn R, Logothetis C: Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients with androgen independent prostate cancer. Proc Am Soc Clin Oncol 13:51(abstract 795), 1994Google Scholar
  68. 68.
    Kudelka A, Edwards C, Freedman R, Girtanner R, Kaplan H, Fishman A, Balat O, Tresukosol D, deLeon CG, Hord M, Finnegan M, Calayag M, Hunter C, Gutterman J, Kavanagh J: A phase I study of the toxicity, pharmacokinetics, and activity of TNP-470 administered to patients with advanced or recurrent squamous cell cancer of the cervix. Proc Am Soc Clin Oncol 14:281(abstract 794), 1995Google Scholar
  69. 69.
    Mellin GW, Katzenstein M: The saga of thalidomide. N Engl J Med 267: 1184–1193, 1238–244, 1962Google Scholar
  70. 70.
    Vogeizang GB, Taylor S, Gordon G, Hess AD: Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transpl Proc 18:904–906, 1986Google Scholar
  71. 71.
    Lim SH, McWannel A, Vora AJ, Boughton BJ: Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation (letter). Lancet 7:117, 1988Google Scholar
  72. 72.
    Saurat JH, Camenzind M, Helg C, Chapiwis B: Thalidomide for graft-versus-host disease after bone marrow transplantation (letter). Lancet 1:359, 1988Google Scholar
  73. 73.
    Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharm Ther 6:303–306, 1965Google Scholar
  74. 74.
    D'Amato RJ, Loughnan MS, Flynn E, Folkmann J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082–4085, 1994Google Scholar
  75. 75.
    Ausprunk DH, Falterman K, Folkman J: The sequence of events in the regression of corneal capillaries. Lab Invest 38:284–294, 1978Google Scholar
  76. 76.
    Kohn EC, Liotta LA: Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55:1856–1862, 1995Google Scholar
  77. 77.
    Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J: Association between expression of activated 72 kDa gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst 85:574–578, 1993Google Scholar
  78. 78.
    Brown PD, Bloxidge RE, Anderson E, Howell A: Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastases 11:183–189, 1993Google Scholar
  79. 79.
    Yashimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, Yachi A: Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int J Cancer 54:614–618, 1993Google Scholar
  80. 80.
    Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087–2091, 1993Google Scholar
  81. 81.
    Beattie GJ, Smyth JF: Early clinical studies of intraperitoneal matrix metalloproteinase inhibitor BB94 in patients with malignant ascites. Eur J Cancer 31A(suppl): 106(abstract 494), 1995Google Scholar
  82. 82.
    O'Byrne K, Macaulay V, Saunders M, Long L, Gleeson F, Ganesan TS, Harris AL, Talbot DC: Phase I study of Batimastat (BB94) in the treatment of malignant pleural effusions. Eur J Cancer 31A(suppl):198(abstract 951), 1995Google Scholar
  83. 83.
    Hellerqvist CG, Thurman GB, Page DL, Wang YF, Russel BA, Montgomery CA, Sundell HW: Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B β-hemolytic streptococcus. J Cancer Res Clin Oncol 120:63–70, 1993Google Scholar
  84. 84.
    Thurman GB, Russel BA, York GE, Wang YF, Page DL, Sundell HW, Hellerqvist CG: Effects of group B streptococcus toxin on long-term survival of mice bearing transplanted Madison lung tumors. J Cancer Res Clin Oncol 120:479–484, 1994Google Scholar
  85. 85.
    DeVore R, Johnson DR, Hellerqvist C, Wakefield G, Browning P, Page D, Sundell H, Johnson DH: A phase I study of the anti-neovascularization drug CM-101. Proc Am Soc Clin Oncol 14:487(abstract 1591), 1995Google Scholar
  86. 86.
    Hellerqvist C, DeVore R, Thurman G, Wamil B, Zhang M, Wakefield G, Sundell H, Carter C, Yan H, Johnson D: Cytokine production in cancer patients receiving the antineovascularization drug CM-101. Proc Am Soc Clin Oncol 14:488(abstract 1592), 1995Google Scholar
  87. 87.
    Kalland T, Alm G, Stalhandske T: Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol 134:3956–3961, 1985Google Scholar
  88. 88.
    Larsson EL, Joki AL, Stalhandske T: Mechanism of action of the new immunomodulator LS 2616 on T cell responses. Int J Immunopharmacol 9:425–431, 1991Google Scholar
  89. 89.
    Kalland T: Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 46:3018–3022, 1986Google Scholar
  90. 90.
    Ichikawa T, Lamb JC, Christensson PI, Hartley-Asp B, Isaacs JT: The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 52:3022–3028, 1992Google Scholar
  91. 91.
    Vukanovic J, Passaniti A, Hirata T, Trayston RJ, Hartley-Asp B, Isaacs JT: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53:1835–1837, 1993Google Scholar
  92. 92.
    Vukanovic J, Hartley-Asp B, Isaacs JT: Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate 26:235–246, 1995Google Scholar
  93. 93.
    Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 55:1499–1504, 1995Google Scholar
  94. 94.
    Borgström P, Torres Filho IP, Vajkoczy P, Strandgarden K, Polacek J, Hartley-Asp B: The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol 34:280–286, 1994Google Scholar
  95. 95.
    Schally AV: Oncologic applications of somatostatin analogues. Cancer Res 48:6977–6985, 1988Google Scholar
  96. 96.
    Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM: Direct inhibitory effects of somatostatin (analogues on the growth of human breast cancer cells. Cancer Res 47:1566–1570, 1987Google Scholar
  97. 97.
    Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M: Somatostatin analogues in the treatment of breast and prostate cancer. J Steroid Biochem Mol Biol 37:1083–1087, 1990Google Scholar
  98. 98.
    Anthony L, Johnson D, Horde K, Shaff M, Winn S, Krozely M, Oates J: Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32:217–223, 1993Google Scholar
  99. 99.
    Gagliardi A, Collins DC: Inhibition of angiogenesis by antiestrogens. Cancer Res 53:533–535, 1993Google Scholar
  100. 100.
    Hong WK, Itri LM: Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS (eds) The Retinoids: Biology, Chemistry and Medicine, Ed 2. Raven Press, Ltd. New York, 1994, pp 597–624.Google Scholar
  101. 101.
    Oikawa T, Hirotani K, Nakamura O, Shudo K, Hiragun A, Iwaguchi T: A highly potent angiogenic activity of retinoids. Cancer Letters 48:157–162, 1989Google Scholar
  102. 102.
    Lippman S, Kessler J, Meyskens J: Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 71:391–405, 493–515, 1987Google Scholar
  103. 103.
    Majewski S, Szmuzio A, Mazczak M, Jablouska S, Bolag W: Synergistic effect of retinoids and interferon α on tumor induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor cell lines. Int J Cancer 57:81–85, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • William J. Gradishar
    • 1
  1. 1.Division of Hematology/Medical Oncology, Department of Medicine and Robert H. Lurie Cancer CenterNorthwestern University Medical SchoolChicagoUSA

Personalised recommendations